Evidence map›Paper›PMID 38625729›Full record

ArticleJMIR formative research2024

Recruitment Strategies in the Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization Study (meSH): Multicenter Survey Study.

Chinonyelum Nwosu, Hamda Khan, Rita Masese, Judith M Nocek, Siera Gollan, Taniya Varughese, Sarah Bourne, Cindy Clesca, Sara R Jacobs, Ana Baumann and 4 more

Registry-linked trialAbstract read
In one paragraph

Article in JMIR formative research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03380351 (The Implementation of Cognitive Screening and Educational Support to Improve Outcomes of Adolescents and Young Adults With Sickle Cell Disease), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03380351 completednot on this map

The Implementation of Cognitive Screening and Educational Support to Improve Outcomes of Adolescents and Young Adults With Sickle Cell Disease: From Clinic to the Community and Back

TypeobservationalSponsorWashington University School of MedicineRan2019 to 2024Enrolled17ConditionsAnemia, Sickle CellArmsSCDIC interventions
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Chinonyelum NwosuDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, TN, United States.ORCID https://orcid.org/0000-0003-1079-7829
Hamda KhanDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, TN, United States.ORCID https://orcid.org/0000-0002-7296-9684
Rita MaseseDuke University, Durham, NC, United States.ORCID https://orcid.org/0000-0002-1431-8840
Judith M Nocek *University of Illinois at Chicago, Chicago, IL, United States.ORCID https://orcid.org/0009-0009-9709-3840
Siera GollanAugusta University, Augusta, GA, United States.ORCID https://orcid.org/0000-0003-2474-1340
Taniya VarugheseWashington University School of Medicine, St Louis, MO, United States.ORCID https://orcid.org/0000-0002-7300-6986
Sarah BourneMedical University of South Carolina, Charleston, SC, United States.ORCID https://orcid.org/0000-0002-7530-037X
Cindy ClescaIcahn School of Medicine at Mount Sinai, New York, NY, United States.ORCID https://orcid.org/0009-0005-1297-5133
Sara R JacobsRTI International, Research Triangle Park, NC, United States.ORCID https://orcid.org/0000-0002-0617-4285
Ana BaumannWashington University School of Medicine, St Louis, MO, United States.ORCID https://orcid.org/0000-0002-4523-0147
Lisa M KlesgesWashington University School of Medicine, St Louis, MO, United States.ORCID https://orcid.org/0000-0001-6237-4743
Nirmish ShahDuke University, Durham, NC, United States.ORCID https://orcid.org/0000-0002-7506-0935
Jane S Hankins *Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN, United States.ORCID https://orcid.org/0000-0003-4439-7321
Matthew P Smeltzer *The University of Memphis, Memphis, TN, United States.ORCID https://orcid.org/0000-0003-1366-9267

Funding

Data Coordinating Center for Sickle Cell Disease Implementation Consortium (SCDIC)U24HL133948 · NHLBI · RESEARCH TRIANGLE INSTITUTE · PI JACOBS, SARA RUBIN, KRONER, BARBARA L · 2016 to 2021
$7.3M
New York City Sickle Cell Implementation Science ConsortiumU01HL133997 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI RICHARDSON, LYNNE D. · 2016 to 2021
$5.4M
The Implementation of Cognitive Screening and Educational Support to Improve Outcomes of Adolescents and Young Adults with Sickle Cell Disease: From Clinic to the Community and BackU01HL133994 · NHLBI · WASHINGTON UNIVERSITY · PI KING, ALLISON A · 2016 to 2021
$5.2M
Improving Sickle cell care in Adolescents & Adults in Chicago (ISAAC)U01HL134042 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI GORDEUK, VICTOR R, HIRSCHTICK, JANA · 2016 to 2021
$5.1M
Implementation of Medical Homes for Evidence Based Care of Adolescents and Adults with Sickle Cell DiseaseU01HL134004 · NHLBI · AUGUSTA UNIVERSITY · PI GIBSON, ROBERT WILLIAM, KUTLAR, ABDULLAH · 2016 to 2021
$5.0M
Improving SCD Care using Web-based Guidelines, Nurse Care Managers and Peer Mentors in Primary Care and Emergency Departments in Central North CarolinaU01HL133964 · NHLBI · DUKE UNIVERSITY · PI SHAH, NIRMISH R, TANABE, PAULA · 2016 to 2021
$4.8M
RE-aiming at Hydroxyurea Adherence for Sickle cell with mHealth (RE-HASH)U01HL133996 · NHLBI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HANKINS, JANE SILVA, KLESGES, LISA M · 2016 to 2021
$4.6M
SC-Links - Linking the Sickle Cell Community, Providers and Systems to Improve Sickle Cell Disease CareU01HL134007 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TREADWELL, MARSHA J, VICHINSKY, ELLIOTT P · 2016 to 2021
$4.1M
Implementation of a Sickle Cell Enhanced Novel Care Network in South Carolina (iSCENSC)U01HL133990 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI FLOREZ, HERMES JOSE · 2016 to 2021
$4.1M
NHLBI NIH HHS U01 HL133964NHLBI NIH HHS U01 HL133990NHLBI NIH HHS U01 HL133994NHLBI NIH HHS U01 HL133996NHLBI NIH HHS U01 HL133997NHLBI NIH HHS U01 HL134004NHLBI NIH HHS U01 HL134007NHLBI NIH HHS U01 HL134042NHLBI NIH HHS U24 HL133948
6 · The paper itself

Abstract

backgroundHydroxyurea is an evidence-based disease-modifying therapy for sickle cell disease (SCD) but is underutilized. The Integration of Mobile Health into Sickle Cell Disease Care to Increase Hydroxyurea Utilization (meSH) multicenter study leveraged mHealth to deliver targeted interventions to patients and providers. SCD studies often underenroll; and recruitment strategies in the SCD population are not widely studied. Unanticipated events can negatively impact enrollment, making it important to study strategies that ensure adequate study accrual.

objectiveThe goal of this study was to evaluate enrollment barriers and the impact of modified recruitment strategies among patients and providers in the meSH study in response to a global emergency.

methodsRecruitment was anticipated to last 2 months for providers and 6 months for patients. The recruitment strategies used with patients and providers, new recruitment strategies, and recruitment rates were captured and compared. To document recruitment adaptations and their reasons, study staff responsible for recruitment completed an open-ended 9-item questionnaire eliciting challenges to recruitment and strategies used. Themes were extrapolated using thematic content analysis.

resultsTotal enrollment across the 7 sites included 89 providers and 293 patients. The study acceptance rate was 85.5% (382/447) for both patients and providers. The reasons patients declined participation were most frequently a lack of time and interest in research, while providers mostly declined because of self-perceived high levels of SCD expertise, believing they did not need the intervention. Initially, recruitment involved an in-person invitation to participate during clinic visits (patients), staff meetings (providers), or within the office (providers). We identified several important recruitment challenges, including (1) lack of interest in research, (2) lack of human resources, (3) unavailable physical space for recruitment activities, and (4) lack of documentation to verify eligibility. Adaptive strategies were crucial to alleviate enrollment disruptions due to the COVID-19 pandemic. These included remote approaching and consenting (eg, telehealth, email, and telephone) for patients and providers. Additionally, for patients, recruitment was enriched by simplification of enrollment procedures (eg, directly approaching patients without a referral from the provider) and a multitouch method (ie, warm introductions with flyers, texts, and patient portal messages). We found that patient recruitment rates were similar between in-person and adapted (virtual with multitouch) approaches (167/200, 83.5% and 126/143, 88.1%, respectively; P=.23). However, for providers, recruitment was significantly higher for in-person vs remote recruitment (48/50, 96% and 41/54, 76%, respectively, P<.001).

conclusionsWe found that timely adaptation in recruitment strategies secured high recruitment rates using an assortment of enriched remote recruitment strategies. Flexibility in approach and reducing the burden of enrollment procedures for participants aided enrollment. It is important to continue identifying effective recruitment strategies in studies involving patients with SCD and their providers and the impact and navigation of recruitment challenges.

trial registrationClinicalTrials.Gov NCT03380351; https://clinicaltrials.gov/study/NCT03380351. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-10.2196/16319.

Indexed as

eHealthhydroxyureainterventionmhealthmobile healthmulticenterrecruitmentsickle cellstrategyutilization

Identifiers

PMID38625729
PMCPMC11061784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.